Evidence map›Paper›PMID 34564390›Full record

ArticleMetabolites2021

Metabolomics-Based Screening of Inborn Errors of Metabolism: Enhancing Clinical Application with a Robust Computational Pipeline.

Brechtje Hoegen, Alan Zammit, Albert Gerritsen, Udo F H Engelke, Steven Castelein, Maartje van de Vorst, Leo A J Kluijtmans, Marleen C D G Huigen, Ron A Wevers, Alain J van Gool and 3 more

Open access · goldAbstract read
In one paragraph

Article in Metabolites, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 2 countries.

Brechtje HoegenDepartment of Human Genetics, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.ORCID 0000-0002-1226-2177
Alan ZammitDepartment of Human Genetics, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
Albert GerritsenDepartment of Human Genetics, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
Udo F H EngelkeRadboud Institute of Molecular Life Sciences, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
Steven CasteleinDepartment of Human Genetics, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
Maartje van de VorstDepartment of Human Genetics, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
Leo A J KluijtmansTranslational Metabolic Laboratory, Department of Laboratory Medicine, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
Marleen C D G HuigenTranslational Metabolic Laboratory, Department of Laboratory Medicine, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
Ron A WeversRadboud Institute of Molecular Life Sciences, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.ORCID 0000-0003-2278-9746
Alain J van GoolRadboud Institute of Molecular Life Sciences, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
Christian GilissenDepartment of Human Genetics, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
Karlien L M CoeneRadboud Institute of Molecular Life Sciences, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
Purva KulkarniRadboud Institute of Molecular Life Sciences, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
Radboud University Nijmegen · NL

Funding

Nederlandse Organisatie voor Wetenschappelijk Onderzoek 917-17-353Nederlandse Organisatie voor Wetenschappelijk Onderzoek X-omics Initiative 184.034.019
6 · The paper itself

Abstract

Inborn errors of metabolism (IEM) are inherited conditions caused by genetic defects in enzymes or cofactors. These defects result in a specific metabolic fingerprint in patient body fluids, showing accumulation of substrate or lack of an end-product of the defective enzymatic step. Untargeted metabolomics has evolved as a high throughput methodology offering a comprehensive readout of this metabolic fingerprint. This makes it a promising tool for diagnostic screening of IEM patients. However, the size and complexity of metabolomics data have posed a challenge in translating this avalanche of information into knowledge, particularly for clinical application. We have previously established next-generation metabolic screening (NGMS) as a metabolomics-based diagnostic tool for analyzing plasma of individual IEM-suspected patients. To fully exploit the clinical potential of NGMS, we present a computational pipeline to streamline the analysis of untargeted metabolomics data. This pipeline allows for time-efficient and reproducible data analysis, compatible with ISO:15189 accredited clinical diagnostics. The pipeline implements a combination of tools embedded in a workflow environment for large-scale clinical metabolomics data analysis. The accompanying graphical user interface aids end-users from a diagnostic laboratory for efficient data interpretation and reporting. We also demonstrate the application of this pipeline with a case study and discuss future prospects.

Indexed as

bioinformatics pipelinebiomarkersclinical applicationdata analysisinherited metabolic diseasesmass spectrometrynext-generation metabolic screeninguntargeted metabolomics

Identifiers

PMID34564390
PMCPMC8470724
OpenAlexW3195246135

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.